



10 ml size, dried

List No. KD 060-610

**ANTIHAEMOPHILIC FACTOR
(HUMAN)
HEMOFIL® HT
Method Four**

Heat Treated

Contents: One bottle 10 ml dried Antihæmophilic Factor (Human), one bottle 10 ml Water for Injections Ph. Eur., one syringe of 10 ml, one syringe needle (21 GA), one double-ended needle, one filter spike, one miniset (21 GA) and directions for use.

FOR INTRAVENOUS ADMINISTRATION.

Administration: See enclosed direction sheet and use as directed by physician.

Stabilised with heparin, not over 1.0 unit (0.010 mg) per ml of reconstituted material. Contains no preservative. Use promptly (within 3 hours) after reconstitution. Do not use if gel forms on reconstitution.

WARNING: Plasma from which this product was derived was found to be nonreactive for hepatitis B surface antigen (HB_sAg) when tested with licenced third generation reagents.

In addition, the process used in the manufacture of this product includes a heating step designed to minimise the risk of transmission of hepatitis. However, no procedure has been shown to be totally effective in removing hepatitis infectivity from Antihæmophilic Factor (Human).

The product and/or its manufacture is covered by Great Britain Patent 1,372,515.

® Registered Trademark

Distributed by:
TRAVENOL LABORATORIES LTD.,
Thetford, Norfolk, England.

POM

PL0116/0150 PA167/7/8

30-6D-02-660A

ANTITHROMPHILIC FACTOR
(HUMAN)
HEMOPIL® HT
Method Four

Heat Treated

List No. KD 060-610

10 ml size, dried



STORE THIS PACKAGE BETWEEN 2 AND 8° C or up to 1 month
(within dating period) at room temperature, not to exceed 25° C.
Avoid freezing, which might damage diluent bottle. Protect from light.

Date stored at room temperature:

This lot contains 260 International Units of AHF activity per vial.
Lot No.: 860621 A370A
Expiry Date: JUN. 89

1.2 to 30-10-86

GRO-C



10 ml size, dried

List No. KD 060-610

**ANTIHAEMOPHILIC FACTOR
(HUMAN)
HEMOPIL® HT
Method Four**

Heat Treated

Contents: One bottle 10 ml dried Antihaemophilic Factor (Human), one bottle 10 ml Water for Injections Ph. Eur., one syringe of 10 ml, one syringe needle (21 GA), one double-ended needle, one filter spike, one miniset (21 GA) and directions for use.

FOR INTRAVENOUS ADMINISTRATION.

Administration: See enclosed direction sheet and use as directed by physician.

Stabilised with heparin, not over 1.0 unit (0.010 mg) per ml of reconstituted material. Contains no preservative. Use promptly (within 3 hours) after reconstitution. Do not use if gel forms on reconstitution.

WARNING: Plasma from which this product was derived was found to be nonreactive for hepatitis B surface antigen (HB_sAg) when tested with licenced third generation reagents.

In addition, the process used in the manufacture of this product includes a heating step designed to minimise the risk of transmission of hepatitis. However, no procedure has been shown to be totally effective in removing hepatitis infectivity from Antihaemophilic Factor (Human).

The product and/or its manufacture is covered by Great Britain Patent 1,372,515.

® Registered Trademark

Distributed by:
TRAVENOL LABORATORIES LTD.,
Thetford, Norfolk, England.

POM

PL0116/0150 PA167/7/8

30-6D-02-660A

Heat Treated

Method Four
HEMOFIL® HT

ANTIHAEMOPHILIC FACTOR

List No. KD 060-610

10 ml size, dried



STORE THIS PACKAGE BETWEEN 2 AND 8° C or up to 1 month
(within dating period) at room temperature, not to exceed 25° C.
Avoid freezing, which might damage diluent bottle. Protect from light.

Date stored at room temperature:

This lot contains 260 International Units of AHF activity per vial.

Lot No.: 660621A370A

Expiry Date: JUN. 88

dem *le 30 10 86*

GRO-C